Jul 27, 2015 - Pancreatic cancer is a highly metastatic disease with a 5 year survival rate of â¼6.0% after diagnosis. The poor outcome of pancreatic cancer is ...
7/27/2015
Abstract 2011: ETV4 promotes pancreatic cancer progression and metastasis
Cancer Research cancerres.aacrjournals.org doi: 10.1158/15387445.AM20142011 Cancer Res October 1, 2014 74; 2011
Abstract 2011: ETV4 promotes pancreatic cancer progression and metastasis Nikhil Tyagi 1, Sanjeev K. Srivastava1, Arun Bhardwaj 1, Sumit Arora1, William E. Grizzle2, Laurie B. Owen1, Ajay P. Singh1, and Seema Singh1 +
Author Affiliations
Proceedings: AACR Annual Meeting 2014; April 59, 2014; San Diego, CA
Abstract Pancreatic cancer is a highly metastatic disease with a 5 year survival rate of ∼6.0% after diagnosis. The poor outcome of pancreatic cancer is largely due to its highly aggressive nature and lack of effective therapies against metastatic disease. Therefore, it is imperative to identify novel molecular targets driving metastatic progression of pancreatic cancer. ETV4, protooncogenic transcription factor, has been shown to be expressed aberrantly in various cancers types and to play important roles in pathobiology; however, its roles in pancreatic cancer have not been defined. We investigated the pathological significance of ETV4 in pancreatic cancer by its silencing in two highly metastatic pancreatic cancer cell lines, Colo357 and ASPC1, and by forced overexpression in weakly tumorigenic BXPC3 cells. Silencing of ETV4 led to decreases in growth, clonogenicity, motility and invasiveness of pancreatic cancer cells, whereas its overexpression had opposite effects. Furthermore, our data demonstrate a correlation with changes in the expression of mesenchymal (Ncadherin, Vimentin, Slug and Snail) and epithelial (E cadherin) markers upon ETV4 modulation, indicating its role in epithelial to mesenchymal transition (EMT). More importantly, our in vivo studies in an orthotopic mouse model of pancreatic cancer demonstrated a direct association of ETV4 overexpression with tumorigenicity and metastatic potential of pancreatic cancer cells. In summary, our studies establish a functional role of ETV4 in pancreatic cancer pathogenesis. Citation Format: Nikhil Tyagi, Sanjeev K. Srivastava, Arun Bhardwaj, Sumit Arora, William E. Grizzle, Laurie B. Owen, Ajay P. Singh, Seema Singh. ETV4 promotes pancreatic cancer progression and metastasis. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 59; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 2011. doi:10.1158/15387445.AM20142011 ©2014 American Association for Cancer Research.
http://cancerres.aacrjournals.org/content/74/19_Supplement/2011.abstract
1/2
7/27/2015
Abstract 2011: ETV4 promotes pancreatic cancer progression and metastasis
http://cancerres.aacrjournals.org/content/74/19_Supplement/2011.abstract
2/2
